TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNAZ Stock Price Chart Interactive Chart >
RNAZ Price/Volume Stats
| Current price | $1.83 | 52-week high | $7.00 |
| Prev. close | $1.80 | 52-week low | $1.52 |
| Day low | $1.75 | Volume | 58,200 |
| Day high | $1.90 | Avg. volume | 25,971 |
| 50-day MA | $2.58 | Dividend yield | N/A |
| 200-day MA | $2.64 | Market Cap | 23.75M |
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Latest RNAZ News From Around the Web
Below are the latest news stories about Transcode Therapeutics Inc that investors may wish to consider to help them evaluate RNAZ as an investment opportunity.
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent PortfolioBOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has filed an International PCT Application (PCT/US21/65580) entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY (the ‘580 application). The ‘580 application, expected to publish in June 2022, represents an extension of TransCode’s use of its patented RNA therapeutic platform to include using patter |
CORRECTION --TransCode TherapeuticsBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode Therapeutics, Inc. (Nasdaq: RNAZ), please note that in the headline, the date of the conference should be 2022, not 2020 as previously stated. The corrected release follows: TransCode Therapeutics to Present at 2022 BIO CEO & INVESTOR CONFERENCE TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will |
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCEBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes has the potential to significantly advance the treatment of cancer, including the company’s lead therapeutic candidate designed to treat metastatic disease. The Company is planning to file an explo |
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect ConferenceBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer. The Company plans to advance its lead therapeutic candidate, designed to treat metastatic disease, into its First in Human clini |
TransCode Therapeutics To Participate at MedInvest Oncology Investor ConferenceBOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company’s lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its F |
RNAZ Price Returns
| 1-mo | -32.97% |
| 3-mo | -16.06% |
| 6-mo | -37.33% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.95% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...